Wes Kaupinen
Chief Executive Officer
Palvella Therapeutics
Palvella Therapeutics develops the QTORIN™ platform, a patented topical drug delivery system designed to achieve therapeutic concentrations in the deep layers of the skin for treating rare genetic dermatological diseases. The company addresses the lack of FDA-approved therapies for these conditions, aiming to provide effective treatment options for patients suffering from mTOR-driven skin disorders.
- Biotechnology
Updated 6 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many rare genetic skin diseases lack FDA-approved therapies, leaving patients without effective treatment options. Developing topical treatments for these conditions is challenging due to difficulties in achieving therapeutic drug concentrations in the deep layers of the skin while minimizing systemic absorption.
Solution
Palvella Therapeutics is developing the QTORIN™ platform, a patented topical drug delivery system designed to deliver therapeutic concentrations of drugs to the deep layers of the skin. The QTORIN™ platform addresses the challenges of topical drug delivery by achieving both effective drug penetration and chemical stability. Palvella's initial product candidate, QTORIN 3.9% rapamycin anhydrous gel, has the potential to impact patients living with mTOR-driven rare genetic skin diseases.
Target Audience
The primary target audience includes individuals suffering from rare genetic skin diseases, particularly those with mTOR-driven disorders, and the healthcare professionals who treat them.
Features
- QTORIN™ platform designed for rapid delivery of therapies to deep skin layers.
- Topical application minimizes systemic absorption compared to oral medications.
- QTORIN™ platform has received Fast Track and Breakthrough Therapy designations from the FDA.